MS
Morgan Stanley
MS has the edge over XRN overall, supported by stronger fundamentals and stronger modeled upside.
XRN
Chiron Real Estate Inc.
XRN offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
MS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
MS's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like MS.
XRN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| N/A | |
| N/A |
XRN's profitability is currently healthy, and its revenue is stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like XRN.
MS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $134 | -29% |
| Fair | 14x | $178 | -5.7% |
| Forward | 14x | $189 | — |
| Current | 15x | $189 | — |
| Expensive | 18x | $223 | +18% |
Historical ranges are pointers, not guarantees.
MS's PE is in its fair range at 15x. If earnings grow as analysts expect, today's price would be 14x next year's earnings.
XRN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 7.6x | $26.58 | — |
| Cheap | 36x | $127 | +378% |
| Fair | 50x | $173 | +550% |
| Expensive | 109x | $381 | +1335% |
Historical ranges are pointers, not guarantees.
XRN has the edge over MS in the historical PE scenario, which offers more potential upside but is not a forecast.
MS Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
MS has the edge over XRN on the outlook, with more favorable earnings and revenue expectations.
XRN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Decline | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect XRN's losses to grow, with revenue declining. However, they disagree widely on these estimates.
MS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.39 | +6.3% |
| Q3 2026 | $12.60 | +29% |
| Q2 2026 | $12.37 | +40% |
| Q1 2026 | $11.04 | +29% |
| Q4 2025 | $10.21 | +28% |
| Q3 2025 | $9.76 | +48% |
| Q2 2025 | $8.84 | +45% |
| Q1 2025 | $8.53 | +55% |
| Q4 2024 | $7.95 | +53% |
MS has the edge over XRN on earnings, with more consistent year-over-year improvement.
XRN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $3.49 | +$3.74 |
| Q2 2026 | $3.71 | +960% |
| Q1 2026 | -$1.12 | -847% |
| Q4 2025 | -$0.91 | -1920% |
| Q3 2025 | -$0.25 | -$0.15 |
| Q2 2025 | $0.35 | +$0.35 |
| Q1 2025 | $0.15 | -87% |
| Q4 2024 | $0.05 | -96% |
XRN has returned to profit: it earned $3.49 per share over the past year, after losing money the year before.
MS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.3B | +12% |
| Q2 2026 | $21.3B | +27% |
| Q1 2026 | $20.6B | +16% |
| Q4 2025 | $17.9B | +10% |
| Q3 2025 | $18.2B | +18% |
| Q2 2025 | $16.8B | +12% |
| Q1 2025 | $17.7B | +17% |
| Q4 2024 | $16.2B | +26% |
MS has the edge over XRN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 32% | -1.2 points |
| Q2 2026 | 34% | +6.9 points |
| Q1 2026 | 34% | +2.8 points |
| Q4 2025 | 32% | +2 points |
| Q3 2025 | 33% | +5.6 points |
| Q2 2025 | 28% | +0.4 points |
| Q1 2025 | 31% | +2.2 points |
| Q4 2024 | 30% | +14 points |
MS's operating margin was 32% last quarter, down 1.2 points from the same quarter a year ago.
XRN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $40.3M | +8.3% |
| Q2 2026 | $39.7M | +4.7% |
| Q1 2026 | $38.1M | +10% |
| Q4 2025 | $38.4M | +9.2% |
| Q3 2025 | $37.2M | +8.7% |
| Q2 2025 | $38M | +11% |
| Q1 2025 | $34.6M | -1.4% |
| Q4 2024 | $35.2M | +6.7% |
XRN's revenue has grown year over year for six quarters in a row: $40M last quarter, up 8.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 65% | N/A |
| Q2 2026 | 75% | N/A |
XRN has the edge over MS on profitability, with a higher operating margin.
MS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$46B | -$42.7B |
| Q2 2026 | -$2.7B | -123% |
| Q1 2026 | -$7.1B | +$16.9B |
| Q4 2025 | -$2.4B | -120% |
| Q3 2025 | -$3.3B | +$14B |
| Q2 2025 | $11.8B | +368% |
| Q1 2025 | -$24B | -650% |
| Q4 2024 | $11.8B | +$29.6B |
MS's free cash flow was −$58.3B over the past year, against −$3.7B the year before. Free cash flow isn't a meaningful measure for financial services companies like MS.
XRN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.3M | -53% |
| Q2 2026 | $19.5M | -12% |
| Q1 2026 | $11.2M | -8.7% |
| Q4 2025 | $21.6M | +5.4% |
| Q3 2025 | $17.6M | +7.8% |
| Q2 2025 | $22.1M | +17% |
| Q1 2025 | $12.3M | -14% |
| Q4 2024 | $20.5M | +13% |
XRN has the edge over MS on cash generation, producing positive trailing cash flow while its opponent burns cash.
MS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -3M shares |
| 1 year | -1.5% | -24M shares |
| 3 years | -4.7% | -77M shares |
| 5 years | -14% | -246M shares |
| Available history | -4.5% | -74M shares |
MS has the edge over XRN on shareholder dilution, with a more favorable share count trend.
XRN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +5K shares |
| 1 year | -1.1% | -153K shares |
| 3 years | +1% | +127K shares |
| 5 years | +3.1% | +399K shares |
| Available history | +75% | +5.7M shares |
XRN has 13M diluted shares, down 1.1% from a year ago.
MS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 7.8x | High |
| Q2 2026 | 7.3x | High |
| Q1 2026 | 8.2x | High |
| Q4 2025 | 8.6x | High |
| Q3 2025 | 8.4x | High |
| Q2 2025 | 8.7x | High |
| Q1 2025 | 8.7x | High |
| Q4 2024 | 7.9x | High |
MS's net debt is about 7.8 years of its operating earnings (EBITDA), down from 8.4 years a year ago. Net leverage isn't a meaningful measure for financial services companies like MS.
XRN Net Leverage
MS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.0 | Neutral |
| Stochastic | 18.7 | Oversold |
MS's weekly RSI is 45 (neutral) and its Stochastic is 19 (oversold).
XRN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 25.3 | Oversold |
| Stochastic | 10.9 | Oversold |
XRN's weekly RSI is 25 (oversold) and its Stochastic is 11 (oversold).
MS PE vs Financial Services Sector
| Metric | MS | Sector median | Relative |
|---|---|---|---|
| PE | 15x | 13x | 15% above |
| PE % | 59 | 63 | 4 pts below |
MS is trading at 15x earnings, a 15% premium to the Financial Services sector's median of 13x.
XRN PE vs Financial Services Sector
| Metric | XRN | Sector median | Relative |
|---|---|---|---|
| PE | 7.6x | 13x | 41% below |
| PE % | 0 | 63 | 63 pts below |
XRN has the edge over MS on valuation relative to its sector.
MS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $186.5 | 1.5% above |
| 20 week MA | $203.3 | 6.9% below |
| 50 week MA | $191.9 | 1.4% below |
| 100 week MA | $164.9 | 15% above |
| 200 week MA | $129.3 | 46% above |
MS has the edge over XRN on trend strength, trading above more of its moving averages.
XRN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 15% below |
| 20 week MA | $34.5 | 23% below |
| 50 week MA | $34.8 | 24% below |
| 100 week MA | $35.5 | 25% below |
| 200 week MA | $41.3 | 36% below |
XRN is in a downtrend: it's below all five of its weekly moving averages, and 36% below its 200-week average.
MS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $51.1 | $68.1 | +33% |
| 2021 | $68.1 | $99.3 | +46% |
| 2022 | $99.3 | $86.1 | -13% |
| 2023 | $86.1 | $93.3 | +8.3% |
| 2024 | $93.3 | $126.8 | +36% |
| 2025 | $126.8 | $181.9 | +43% |
| 2026 YTD | $181.9 | $189.2 | +4% |
MS has the edge over XRN on returns for 2026, with the stronger performance.
XRN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $64.6 | $67.0 | +3.7% |
| 2021 | $67.0 | $85.8 | +28% |
| 2022 | $85.8 | $46.9 | -45% |
| 2023 | $46.9 | $55.5 | +18% |
| 2024 | $55.5 | $38.1 | -31% |
| 2025 | $38.1 | $33.5 | -12% |
| 2026 YTD | $33.5 | $26.6 | -21% |
XRN has finished lower in three of the last six years. It's down 21% so far in 2026.